NASDAQ · OMIC
Healthcare · Medical - Instruments & Supplies
$20.01
Up+$0.00 (+0.00%)
Updated Aug 25, 2026, 6:53 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
OMIC does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning OMIC.
OMIC research
Company profile and research snapshot.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 9, 2024 | Goldman Sachs | Neutral | — |
| May 15, 2024 | Goldman Sachs | Neutral | — |
| Mar 20, 2024 | UBS | Neutral | — |
| Jan 23, 2024 | Goldman Sachs | Neutral | — |
| Jan 22, 2024 | Goldman Sachs | Neutral | — |
No generated briefing is available yet.
Benzinga · Feb 21, 2025
Singular Genomics, a life science technology company, has announced the closing of its acquisition by Deerfield Management Company. The transaction will provide Singular Genomics with greater flexibility to continue advancing its business strategy.
Benzinga · Dec 23, 2024
Singular Genomics, a life science technology company, has entered into a definitive merger agreement to be acquired by Deerfield Management Company for $20.00 per share in cash, representing a 254% premium to the last closing share price.
GlobeNewswire Inc. · Oct 9, 2024
Basecamp Research, an AI company, has entered a multi-year collaboration with the Liu Lab at the Broad Institute to develop novel genetic medicines. The company has also completed a $60 million Series B financing led by Singular.
Benzinga · Sep 19, 2024
Singular Genomics has received a non-binding acquisition proposal from Concentra Biosciences and Tang Capital to acquire the company's outstanding shares for $12 per share in cash or a contingent value right.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OMIC.
No results
No recent SID articles mention OMIC.
